Bifogade filer
Press release from PAXMAN AB’s 2025 Annual General Meeting
Kurs
-5,01%
Likviditet
5,42 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-11-20 | 07:00 | Kvartalsrapport 2026-Q3 |
| 2026-08-21 | 07:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-21 | 07:00 | Kvartalsrapport 2026-Q1 |
| 2026-02-27 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-14 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-19 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2025-05-16 | - | Årsstämma |
| 2025-05-16 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-08 | - | Extra Bolagsstämma 2025 |
| 2025-02-21 | - | Bokslutskommuniké 2024 |
| 2024-11-15 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-24 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-05-23 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2023-05-24 | - | Årsstämma |
| 2023-05-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-27 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2022-05-25 | - | Årsstämma |
| 2022-05-25 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-19 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-20 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-28 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2020-05-27 | - | Årsstämma |
| 2020-05-27 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-21 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2019-05-23 | - | Årsstämma |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-30 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2018-05-24 | - | Årsstämma |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
PAXMAN´s AGM was held today, 16 May 2025, at NetPort in Karlshamn.
Almost 51,7 % of all issued shares were represented at the meeting. After the formal AGM, CEO Richard Paxman gave a company presentation and responded to questions from the attending shareholders.
In accordance with the proposal submitted by the Nomination Committee, the AGM resolved that the Board of Directors shall consist of seven Board Members without deputy members. The Board was re-elected in its entirety. The board will consist of the following members up to the AGM 2025: Per-Anders Johansson (Chairman of the Board), Robert Kelly, Björn Littorin, Glenn Paxman, Richard Paxman, Maria Bech and Karen Giddings Clakely.
Also in accordance with the Nomination Committee’s proposal, the accountancy firm Ernst & Young AB was elected. EY has notified that Henrik Rosengren will be the chief auditor.
The Meeting further resolved that the total fees payable to the Board, excluding travel expenses, will be 550,000 SEK per annum, of which 150,000 SEK payable to the Chairman of the Board and 100,000 SEK to each of the Board Members elected by the AGM who are not employed by the company.
The Meeting also resolved to approve the Board of Directors’ proposal to implement an employee option program and to issue warrants.
All resolutions made by the AGM were unanimous.
Contacts
Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se
About Us
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 6,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK), Houston, Texas (US) and Toronto, Ontario (CA).
The PAXMAN share is listed on Nasdaq First North Growth Market.
FNCA Sweden AB is the company’s Certified Adviser.